SOUTH SAN FRANCISCO, Calif. — October 16, 2025 — Leads & Copy — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company, has announced that CEO and Co-Founder Timothy Lu, MD, PhD, will present at Chardan’s 9th Annual Genetic Medicines Conference on October 21, 2025, in New York, NY.
Management will also be available for one-on-one meetings with registered investors. A live webcast of the presentation will be available on the company’s website.
Senti Bio is developing cell and gene therapies using its proprietary Gene Circuit platform. The company’s pipeline includes cell therapies engineered with Gene Circuits targeting liquid and solid tumor indications. Senti Bio has also demonstrated the potential of Gene Circuits in other modalities and diseases outside of oncology through partnerships.
For more information, visit www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences).
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
SNTI@jtcir.com
Source: Senti Biosciences, Inc.
